LGVN (Longeveron) Accounts Payable: $0.29 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LGVN Longeveron Inc LGVN
45 GF Score
Price $0.61
GF Value $0.38
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Longeveron Accounts Payable?

Longeveron LGVN +1.40% 45 Accounts Payable is $0.29 Mil as of Mar. 2026. GuruFocus rates LGVN with a GF Score™ of 45/100 and a GF Value™ of $0.38 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Longeveron's Accounts Payable for the quarter that ended in Mar. 2026 was $0.29 Mil.

Longeveron's quarterly Accounts Payable declined from Sep. 2025 ($1.08 Mil) to Dec. 2025 ($0.42 Mil) and declined from Dec. 2025 ($0.42 Mil) to Mar. 2026 ($0.29 Mil).

Longeveron's annual Accounts Payable declined from Dec. 2023 ($0.64 Mil) to Dec. 2024 ($0.10 Mil) but then increased from Dec. 2024 ($0.10 Mil) to Dec. 2025 ($0.42 Mil).

Longeveron Accounts Payable Historical Data

* Premium members only.

The historical data trend for Longeveron's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longeveron Accounts Payable Chart

Longeveron Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 0.65 1.75 0.64 0.10 0.42

Longeveron Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.70 1.08 0.42 0.29
LGVN
45GF Score
Longeveron Inc LGVN
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longeveron Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.29 Mil mean?
Longeveron (LGVN) has a Accounts Payable of $0.29 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Longeveron and its competitors.
Is Longeveron's Accounts Payable too high?
Longeveron's current Accounts Payable is $0.29 Mil. Overall, Longeveron has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Longeveron's Accounts Payable compare to MRKR and PLUR?
Longeveron's Accounts Payable of $0.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Longeveron and its competitors. Longeveron's current Accounts Payable is $0.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longeveron stock overvalued right now?
Based on GuruFocus' analysis, Longeveron (LGVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.61 — trading 60.8% above its estimated fair value. The current Accounts Payable is $0.29 Mil. Longeveron's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Longeveron (LGVN), the current Accounts Payable is $0.29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Longeveron (LGVN) Overvalued in 2026?

Based on GuruFocus' analysis, Longeveron stock appears to be overvalued. The current stock price of $0.61 is trading 60.8% above its estimated GF Value™ of $0.38. GuruFocus considers Longeveron to be Significantly Overvalued.

Key valuation signals for LGVN:

  • Accounts Payable: $0.29 Mil
  • GF Value™: $0.38 vs. price of $0.61 (60.8% above fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the LGVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Longeveron Business Description

Address 1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
45GF Score

Get the complete analysis for LGVN

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.61
Price
$0.38
GF Value